SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-016281
Filing Date
2021-01-25
Accepted
2021-01-25 16:33:30
Documents
12
Period of Report
2021-01-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d114490d8k.htm   iXBRL 8-K 22235
  Complete submission text file 0001193125-21-016281.txt   143943

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aldx-20210121.xsd EX-101.SCH 3067
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20210121_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20210121_pre.xml EX-101.PRE 11406
5 EXTRACTED XBRL INSTANCE DOCUMENT d114490d8k_htm.xml XML 3362
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 21549990
SIC: 2834 Pharmaceutical Preparations